Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
27 drugs in development
By Therapeutic Area
top 6
R&D Momentum
100/100
Pipeline Velocity
87/100
Trial Completion Rate
77/100
Pipeline Concentration
21/100
Pipeline Freshness
75/100
Strategic Signals
Activity
Last 14 days
A Randomized Phase II Study to Evaluate the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy
Does Propranolol, a Beta Blocker, Attenuate Stress-Induced Drinking?
Characterization of Immune Response to Intradermal Influenza Vaccination
Developing a Novel Human Laboratory Paradigm for AUD Medication Screening
Phase 2 Study of Apremilast in Women and Men With Alcohol Use Disorder
An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)
Safety, Feasibility, and Tolerability of Psilocybin Treatment for Individuals With Functional Impairment Related to Mood, Anxiety, Trauma and/or Addiction Symptoms: An Open-label Proof-of-concept Study
Characterization of Immune Response to Intradermal Influenza Vaccination
Metabolic Heterogeneity Underlying Hypertriglyceridemia: Hepatic Triglyceride Biosynthesis in Humans With Different Insulin Resistance Phenotypes
Community Health Equity Accelerator (CHEA): Community-Academic Asthma Partnership, Pediatric Asthma Intervention
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)